From Name:
From Email:
To Name:
To Email:

Optional Message:

New small molecule drug shows promise in refractory rheumatoid arthritis

from The Pharmaceutical Journal

Rheumatoid arthritis patients who do not respond to treatment with biologic therapies may find relief in baricitinib, a new small molecule drug, according to a study published in The New England Journal of Medicine. After 12 weeks of treatment, a daily dose of baricitinib led to a 20 percent improvement in disease for 55 percent of patients with moderate to severe disease. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063